Keytruda combinations for uveal melanoma – pro
here are cases reports and case series suggesting effectiveness of Taxol, carboplatin and pembrulizumab in uveal melanoma, but no prospective studies. Algazi et al presented 58 stage IV uveal melanoma patients received PD-1 or PD-L1 antibodies between 2009 and 2015 at nine academic centers. The response rate was 3.6%, a dismal resutl and he concluded that PD-1 and PD-L1 antibodies rarely confer durable remissions in patients with metastatic uveal melanoma. he concldued that PD-1 and PD-L1 antibodies rarely confer durable remissions in patients with metastatic uveal melanoma.
Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344-3353.
Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now?. Ther Adv Med Oncol. 2018;10:1758834018757175.
Kottschade LA, McWilliams RR, Markovic S, et al. The use of pembrolizumab for the treatment of metastatic uveal melanoma. ASCO Meeting Abstracts 2015; 33: 9010.
Piperno-Neumann S, Servois V, Mariani P. Activity of anti-PD1 drugs in uveal melanoma patients. J Clin Oncol 2016; 34(Suppl.): 9588.